Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twelve-Month Open-Label Safety Study of Polyquaternium-Preserved DuoTrav APS
2009-013178-42Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Jul 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of travoprost + timolol in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Alcon Inc. Primary endpoint: Long-term safety of polyquaternium-preserved DuoTrav APS. Started Jul 2009; status: completed.
02
Drugs
travoprost + timolol
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2009-013178-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013178-42.